📅 PubMed Daily Triage — 2026-08-05

Run ID: 2026-08-05-attempt2-20260805T092420Z Window: 2026-08-04T00:00:00Z → 2026-08-05T23:59:59Z (CRDT) Topics scanned: 10 watchlist topics + sentinel broad scan Articles total: 25 | 🔴 HIGH: 14 | ⚪ STANDARD: 11 | LOW/archive: 0 Unsolicited finds: 1 CBC/ML hematology: 0 new articles (topic returned 0 results this window) Run status: PARTIAL_SUCCESS

🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic

Hematologic Malignancies

[10/10] Optical genome mapping refines diagnosis of high-grade myeloid neoplasms through detection of MECOM rearrangements cryptic to conventional karyotype. PMID: 42551945 | Journal: Am J Clin Pathol | Date: 2026-08-04 Authors: Salcedo-Porras N et al. Topics: hematologic_malignancies Study design: cohort_study | Species: human | N: 252 Evidence maturity: Validated | Access: Abstract only Score: novelty=3/3 · relevance=3/3 · design=2/2 · unmet_need=2/2 Key finding: OGM doubled MECOM rearrangement detection rate (12/252; 4.7%) vs combined karyotype+FISH (6/12 detected); 6 cryptic cases identified with normal karyotypes, complex karyotypes lacking chr3 involvement, or culture failure; diverse partner loci resolved (GATA2, THADA, MYC, CDK6, MSI2); diagnostic/risk reclassification in 5 cases. Triage reason: OGM doubled MECOM-r detection vs karyotype+FISH in 252 consecutive AML specimens; 6 cryptic high-risk rearrangements missed by standard cytogenetics; partner locus resolution enabled risk reclassification in 5 cases; strong case for OGM integration into HGMN diagnostic workflow. Flag: 🟢 NEAR_TERM_IMPLEMENTABLE — Near-term implementable finding

[9/10] Early Follicular Lymphoma Grading via PET-CT Fusion and Bayesian Deep Learning. PMID: 42552270 | Journal: J Imaging Inform Med | Date: 2026-08-04 Authors: Qian C et al. Topics: hematologic_malignancies, ai_clinical_diagnostics Study design: original_research | Species: human | N: 837 Evidence maturity: Exploratory | Access: Abstract only Score: novelty=3/3 · relevance=3/3 · design=2/2 · unmet_need=1/2 Key finding: DDCGAN-fused PET-CT + Bayesian ResNet achieves accuracy 0.871, precision 0.875, macro-F1 0.816 for FL grading (including FL I/II/DLBCL distinction) on multi-center dataset (n=837); outperforms single-modality and prior fusion models; Bayesian uncertainty quantification resolves classification ambiguity. Triage reason: Multi-center n=837 PET-CT fusion + Bayesian DL framework for FL grading; accuracy 0.871; dual-relevance to hematologic malignancies and AI diagnostics; biopsy-free FL grading has direct clinical workflow utility; uncertainty quantification is a practical clinical addition. Flag: 🟣 PROMISING_PRELIMINARY — Multi-center AI for non-invasive FL grading; external prospective validation needed

Early Cancer Detection

[10/10] Early-life sugar restriction causally reduces adult cancer incidence and slows biological aging. PMID: 42550905 | Journal: Proc Natl Acad Sci U S A | Date: 2026-08-04 Authors: Zhu C et al. Topics: aging_longevity, early_cancer_detection Study design: cohort_study | Species: human | N: 64,761 Evidence maturity: Validated | Access: Publisher full text Score: novelty=3/3 · relevance=3/3 · design=2/2 · unmet_need=2/2 Key finding: Early-life sugar restriction (UK rationing natural experiment, n=64,761): dose-dependent reductions in adult cancer incidence (liver/IHBD HR 0.31, prostate HR 0.48, breast HR 0.64, rectum HR 0.60, lung HR 0.59); longer leukocyte telomeres (~2.2 fewer biological aging years) and lower Granzyme B in rationed cohorts; persistent healthier dietary behaviors five decades later. Triage reason: Causal evidence from natural experiment (n=64,761) linking early-life sugar to adult cancer and aging biomarkers; five cancer types with strong hazard ratios; dual behavioral and biological mechanism; direct policy implications for early-life nutrition guidelines; University of Cambridge. Flag: 🔴 EARLY_CANCER_DETECTION — Early cancer detection or prevention

[10/10] Integrative cfDNA profiling from low-pass whole-genome sequencing enables tissue-of-origin prediction in cancer. PMID: 42552276 | Journal: Mol Biomed | Date: 2026-08-05 Authors: Zhang Y et al. Topics: early_cancer_detection, ai_clinical_diagnostics Study design: original_research | Species: human | N: 3,035 Evidence maturity: Validated | Access: Publisher full text Score: novelty=3/3 · relevance=3/3 · design=2/2 · unmet_need=2/2 Key finding: Stacked ensemble ML classifier integrating 11 multidimensional cfDNA features achieves 80%/90% top-1/top-2 accuracy across 17 cancer types in independent validation cohort (n=1,221); performance retained at low tumor fraction (71%/85%); nucleosome positioning, fragment size distribution, and repeat elements are key contributors; 73.3% TOO match in cancers of unknown primary. Triage reason: 11-feature cfDNA ensemble achieves 80%/90% top-1/top-2 accuracy across 17 cancers in independent validation (n=1,221); low tumor fraction performance (71%) enables early/residual disease application; 73% CUP accuracy addresses major unmet clinical need; Geneseeq industrial translational pathway. Flag: 🔴 EARLY_CANCER_DETECTION — Early cancer detection or prevention

[8/10] Combining circulating tumor cells and tumor-derived extracellular vesicles for prognosis stratification in patients with metastatic breast cancer. PMID: 42551245 | Journal: ESMO Open | Date: 2026-08-04 Authors: Nicolo E et al. Topics: early_cancer_detection Study design: cohort_study | Species: human | N: 740 Evidence maturity: Validated | Access: Publisher full text Score: novelty=2/3 · relevance=3/3 · design=2/2 · unmet_need=1/2 Key finding: tdEV cut-off >20/7.5ml independently associated with nearly doubled mortality risk in MBC; CTChigh/tdEVhigh identifies worst prognostic subgroup; tdEVhigh retains independent mortality association in CTClow patients; validated in STIC CTC Phase III cohort (n=385). Triage reason: Two-cohort validation (training n=355 + Phase III validation n=385) of tdEV as CTC complement in MBC; CellSearch-compatible ACCEPT software; independent prognosis in CTClow subgroup; ESMO Open; Institut Curie and Weill Cornell collaboration. Flag: 🟣 PROMISING_PRELIMINARY — Two-cohort validated tdEV biomarker; clinical utility requires prospective study

AI / Clinical Diagnostics

No high-priority finds today (best candidate scored 10/10)

Precision Oncology & Genomics

[9/10] Functional profiling of ovarian cancer models reveals Bcl-xL/NOTCH targeting to overcome resistance. PMID: 42552331 | Journal: NPJ Precis Oncol | Date: 2026-08-04 Authors: Gudoityte G et al. Topics: precision_oncology_genomics, novel_therapeutics_immunotherapy Study design: original_research | Species: human | N: 35 Evidence maturity: Exploratory | Access: Publisher full text Score: novelty=3/3 · relevance=3/3 · design=2/2 · unmet_need=1/2 Key finding: High-throughput profiling of 528 compounds across 35 patient-derived OC models (22 patients, 7 subtypes) identifies Bcl-xL dependency with selective therapeutic window vs fibroblasts and healthy bone marrow; NOTCH activation is the determinant of Bcl-xL resistance by proteomics; gamma-secretase inhibition restores Bcl-xL sensitivity and re-sensitizes to carboplatin in long-term washout assays. Triage reason: 35 patient-derived OC models, 29,000+ drug response measurements across 528 compounds; NOTCH-modulated Bcl-xL vulnerability as actionable target in platinum-resistant OC; gamma-secretase + Bcl-xL restores platinum sensitivity; NPJ Precis Oncol; Karolinska SciLifeLab. Flag: 🟣 PROMISING_PRELIMINARY — Comprehensive PDX profiling; clinical validation of Bcl-xL/NOTCH combo needed

Novel Therapeutics / Immunotherapy

[10/10] Targeting peripheral 5-HT(2A)R enhances antitumor immunity in colorectal cancer. PMID: 42551424 | Journal: Cell | Date: 2026-08-04 Authors: Wen Y et al. Topics: novel_therapeutics_immunotherapy Study design: original_research | Species: mixed | N: N/A Evidence maturity: Exploratory | Access: Abstract only Score: novelty=3/3 · relevance=3/3 · design=2/2 · unmet_need=2/2 Key finding: Non-brain-penetrant 5-HT2AR agonist IHCH-8110 activates enteric glial cell 5-HT2AR, inducing CXCL10/IL-18 to recruit and polarize CD8+ T cells in the CRC tumor microenvironment, converting immune-cold tumors to immunotherapy-responsive state with superior efficacy in combination with PD-1 blockade. Triage reason: Cell publication identifying novel peripheral 5-HT2AR → enteric glial → CXCL10/IL-18 → CD8+ T cell recruitment axis in CRC; IHCH-8110 as brain-penetrant-avoidant agonist enabling immunotherapy sensitization without CNS effects; strong PD-1 combination data; paradigm-shifting neuro-oncology intersection with immediate translational relevance. Flag: 🟠 NOVEL_TREATMENT — Novel or significantly improved treatment

[10/10] Functional restoration of immune defects in STAT1 gain-of-function disease following stem cell gene editing. PMID: 42550765 | Journal: Blood | Date: 2026-08-04 Authors: Torrance R et al. Topics: rare_diseases, novel_therapeutics_immunotherapy Study design: original_research | Species: mixed | N: N/A Evidence maturity: Exploratory | Access: Abstract only Score: novelty=3/3 · relevance=3/3 · design=2/2 · unmet_need=2/2 Key finding: Adenine base editing of recurrent STAT1 GOF p.T385M mutation achieves >90% correction efficiency in patient T cells and HSCs without significant off-target effects; corrected cells functionally restore STAT1 phosphorylation, interferon-stimulated gene expression (OAS1), and IL-17 production; edited HSCs retain multilineage differentiation and sustain corrected allele at 16 weeks in humanized mice. Triage reason: First application of adenine base editing to a dominant gain-of-function immunodeficiency; >90% correction efficiency in patient HSCs; Blood publication; UCL/Boston Children's consortium; could replace high-morbidity allogeneic HSCT; approach broadly applicable to other heterozygous dominant GOF disorders. Flag: 🟠 NOVEL_TREATMENT — Novel or significantly improved treatment

[9/10] beta-glucan elicits APOE-dependent peripheral trained immunity to suppress hepatocellular carcinoma. PMID: 42552059 | Journal: J Immunother Cancer | Date: 2026-08-04 Authors: Jiang N et al. Topics: novel_therapeutics_immunotherapy Study design: original_research | Species: mixed | N: N/A Evidence maturity: Exploratory | Access: Publisher full text Score: novelty=3/3 · relevance=3/3 · design=2/2 · unmet_need=1/2 Key finding: WGP preconditioning induces APOE+ macrophage trained immunity reducing lipid accumulation and ER stress in orthotopic HCC models; APOE deletion abrogates antitumor effects; adoptive transfer of WGP-trained macrophages suppresses HCC; WGP + anti-PD-L1 achieves superior tumor control vs monotherapy; WGP induces trained immunity in human monocytes. Triage reason: Novel APOE-dependent trained immunity mechanism for HCC immunotherapy; beta-glucan WGP is clinically safe and widely available; superior combo with anti-PD-L1; scRNA-seq + adoptive transfer mechanistic rigor; human monocyte validation; J Immunother Cancer. Flag: 🟣 PROMISING_PRELIMINARY — Novel APOE+ trained immunity mechanism; human translational validation needed

[9/10] Safety, biodistribution, and exploratory clinical outcomes of a novel intra-articular IL-1Ra gene therapy (PCRX-201) in moderate-to-severe knee osteoarthritis: 2-year results of a phase 1 study. PMID: 42552219 | Journal: Ann Rheum Dis | Date: 2026-08-04 Authors: Cohen S et al. Topics: rare_diseases, novel_therapeutics_immunotherapy Study design: clinical_trial | Species: human | N: 72 Evidence maturity: Exploratory | Access: Abstract only Score: novelty=3/3 · relevance=3/3 · design=1/2 · unmet_need=2/2 Key finding: Single intra-articular PCRX-201 injection demonstrated safety with very limited extrajoint biodistribution; most common AE was transient knee effusion (reduced with glucocorticoid pretreatment: 36% vs 61%); exploratory outcomes showed sustained improvements in pain, stiffness, and function at 2 years regardless of neutralizing antibody status. Triage reason: Phase 1 gene therapy for OA with inflammation-inducible promoter enabling smart dosing; 2-year safety and sustained clinical benefit; very limited systemic distribution; no currently approved DMOAD (500M+ OA patients globally); Ann Rheum Dis; Pacira BioSciences. Flag: 🟣 PROMISING_PRELIMINARY — Phase 1 OA gene therapy; 2yr safety + sustained efficacy signal

Cardiovascular-Metabolic

[10/10] Comparative effectiveness of sodium-glucose cotransporter-2 versus dipeptidyl peptidase-4 inhibitors on all-cause mortality in type 2 diabetes: a multinational propensity score-matched cohort study. PMID: 42551692 | Journal: Diabetes Metab | Date: 2026-08-04 Authors: Li CY et al. Topics: cardiovascular_metabolic Study design: cohort_study | Species: human | N: 323,900 Evidence maturity: Validated | Access: Abstract only Score: novelty=3/3 · relevance=3/3 · design=2/2 · unmet_need=2/2 Key finding: SGLT2i associated with 49% lower all-cause mortality vs DPP-4i over 5 years (HR 0.513; 95% CI 0.502-0.525; P<0.001); 5-year cumulative mortality 13.16% vs 26.05%; consistent across sex, age, glycemic control subgroups; validated in independent Hong Kong/Singapore cohort. Triage reason: Largest real-world SGLT2i vs DPP4i mortality comparison (n=323,900 matched pairs); 49% all-cause mortality reduction confirmed across all subgroups and externally validated; direct guideline-supporting evidence reinforcing SGLT2i first-line preference in T2DM. Flag: 🟢 NEAR_TERM_IMPLEMENTABLE — Near-term implementable finding

[9/10] Plasma proteomics linking primary and secondary diseases: Insights into molecular mediation from UK Biobank data. PMID: 42551443 | Journal: Med | Date: 2026-08-04 Authors: Qian H et al. Topics: aging_longevity, cardiovascular_metabolic Study design: cohort_study | Species: human | N: 53,030 Evidence maturity: Validated | Access: Abstract only Score: novelty=3/3 · relevance=3/3 · design=2/2 · unmet_need=1/2 Key finding: 998 significant protein-mediation pathways involving 337 unique plasma proteins identified in UK Biobank (n=53,030); GDF15 consistently mediates diabetes to cardiovascular disease; ACE2 links poorly controlled diabetes to nerve root disorders; 44 proteins with Mendelian randomization-supported causal roles; mediator proteins improve ML-based secondary disease risk prediction. Triage reason: Comprehensive plasma proteomics mediation map (53,030 participants); 998 pathways; GDF15/ACE2 MR-validated as causal mediators; ML risk models improved; NIH/AHA funded; Med (Cell Press) journal; University of Michigan. Flag: 🟣 PROMISING_PRELIMINARY — Large-scale proteomics mediation map; clinical translation pending

[8/10] Safety and efficacy of glucagon like peptide-1 receptor agonism-based therapies in end-stage renal disease: A systematic review and meta-analysis. PMID: 42551699 | Journal: Endocr Pract | Date: 2026-08-04 Authors: Dutta D et al. Topics: cardiovascular_metabolic Study design: meta_analysis | Species: human | N: 388 Evidence maturity: Exploratory | Access: Abstract only Score: novelty=2/3 · relevance=3/3 · design=1/2 · unmet_need=2/2 Key finding: Semaglutide in ESRD produces significant weight reduction at 6m (-3.68kg) and 12m (-7.00kg); HbA1c reductions significant at 12m (-0.75%); AEs in 44% (GI dominant, mostly mild); discontinuation 9%; results primarily hypothesis-generating; prospective RCTs urgently needed. Triage reason: First systematic review for GLP-1 RA in ESRD; semaglutide significant weight reduction at 12m (-7kg) with acceptable AE profile; addresses critical data gap (ESRD excluded from major GLP-1 trials); ESRD is high cardiovascular risk, high mortality, high unmet need population. Flag: 🟣 PROMISING_PRELIMINARY — First SRM in ESRD; evidence preliminary, RCT urgently needed

[8/10] Methionine tuning for health without frailty. PMID: 42551409 | Journal: Cell Metab | Date: 2026-08-04 Authors: Garrido A et al. Topics: aging_longevity, cardiovascular_metabolic Study design: editorial | Species: human | N: N/A Evidence maturity: Exploratory | Access: Abstract only Score: novelty=2/3 · relevance=3/3 · design=1/2 · unmet_need=2/2 Key finding: Moderate methionine supplementation to low-protein Mediterranean-inspired diet activates GH-GLP-1-FGF21 hormonal axis, reducing adiposity and frailty without caloric restriction; mechanism explains why plant-rich diets may promote longevity while sometimes compromising physical robustness. Triage reason: Cell Metabolism editorial (NIH NIA, de Cabo lab) identifying GH-GLP-1-FGF21 axis linking methionine to anti-frailty; cross-relevant to GLP-1 watchlist topic and aging longevity; primary research (Fanti et al.) should be located for full scoring. Flag: 🟣 PROMISING_PRELIMINARY — Cell Metabolism; GH-GLP-1-FGF21 longevity mechanism; seek primary Fanti et al. article

Aging & Longevity

No high-priority finds today (best candidate scored 10/10)

Rare Diseases

No high-priority finds today (best candidate scored 10/10)

🟢⚪ STANDARD (5–7) — Top by Topic

Hematologic Malignancies

42551830 · Oncogenic Role of BCL6 Rearrangement: A Focus on Follicular and Marginal Zone Lymphomas. · 6/10 · Hematologic Malignancies → Review synthesizes BCL6 rearrangement oncogenic mechanisms and clinical significance in FL and MZL, with implications for diagnostic classification and BCL6-targeted treatment strategies. Flag: ⬜ NONE — Standard addition

42551701 · Body mass index and outcomes after CD19 CAR T-cell therapy for relapsed/refractory B-cell lymphoma. · 6/10 · Hematologic Malignancies → BMI modulates outcomes (response, toxicity, and/or survival) after CD19 CAR-T cell therapy for relapsed/refractory B-cell lymphoma; specific findings require abstract review. Flag: ⬜ NONE — Standard addition

42551920 · Laboratory characteristics of direct antiglobulin test-positive anemia in patients with newly diagnosed multiple myeloma. · 5/10 · Hematologic Malignancies → Characterization of laboratory features of direct antiglobulin test-positive anemia at multiple myeloma diagnosis; potentially relevant to anemia management and workup in MM. Flag: ⬜ NONE — Standard addition

Early Cancer Detection

42551913 · Enriching Microbial Cell-Free DNA in Clinical Metagenomics Using Epigenetic Filters. · 6/10 · Liquid Biopsy / Infectious Disease → EpiMeta-seq exploits DNA methylation differences between microbial and human genomes to enrich microbial cfDNA; achieves 24.5-fold enrichment for fungi, 11.4-fold for bacteria in spike-in experiments; 10.0-fold increase in microbial reads/million in 23 clinical plasma samples across 12 pathogens. Flag: ⬜ NONE — Standard addition

42551126 · Size-exclusion chromatography for extracellular vesicles collection as liquid biopsies. · 5/10 · Liquid Biopsy Methods → Size-exclusion chromatography enables efficient EV collection for liquid biopsy applications; characterization of SEC performance for EV isolation from plasma. Flag: ⬜ NONE — Standard addition

Precision Oncology & Genomics

42552318 · Multi-omics integration unravels four molecular subgroups of corticotroph pituitary neuroendocrine tumours with distinct clinicopathological features. · 7/10 · Precision Oncology / Rare Disease → Multi-omics integration of corticotroph pituitary NETs reveals four distinct molecular subgroups with unique clinicopathological profiles; subgroup stratification may inform personalized treatment selection for Cushing's disease and Nelson's syndrome. Flag: ⬜ NONE — Standard addition

42552314 · Maternal hyperglycemia-induced O-GlcNAcylation of CaMKIIdelta promotes cardiac remodeling. · 6/10 · Cardiovascular Epigenetics → Maternal hyperglycemia induces O-GlcNAcylation of CaMKIIδ promoting cardiac remodeling; epigenetic mechanism linking gestational diabetes to offspring cardiac outcomes. Flag: ⬜ NONE — Standard addition

42551191 · A mouse PDX clinical trial reveals broad efficacy of niraparib and vc-seco-DUBA anti-HER2 ADC SYD985 in HER2/neu expressing endometrial cancer. · 5/10 · Targeted Therapy / Endometrial Cancer → Niraparib (PARP inhibitor) combined with SYD985 (vc-seco-DUBA HER2 ADC) demonstrates broad efficacy in HER2+ endometrial cancer PDX models, supporting combination strategy evaluation in clinical trials. Flag: ⬜ NONE — Standard addition

Cardiovascular-Metabolic

42552240 · SGLT2 Inhibitor Use in Type 2 Diabetes in England: A Population-Based Cross-Sectional Study of Uptake of NICE Guidance. · 5/10 · Health Policy / Cardiometabolic → Population-based analysis of real-world SGLT2 inhibitor uptake in T2DM in England relative to NICE guidance; identifies implementation gaps and determinants of uptake. Flag: ⬜ NONE — Standard addition

Rare Diseases

42551715 · Clinical characteristics and outcomes of people with cystic fibrosis with homozygous minimal function genotypes compared to those with F508del/minimal function genotypes. · 6/10 · Rare Disease / Cystic Fibrosis → Comparison of CF clinical characteristics and outcomes between homozygous minimal function and F508del/minimal function genotypes; specific outcome differences require abstract review. Flag: ⬜ NONE — Standard addition

42551284 · Phenotypic and Genetic Characterization of 64 Egyptian Children With Neuronal Ceroid Lipofuscinosis. · 6/10 · Rare Disease / Neurological → Phenotypic and genetic characterization of 64 Egyptian children with NCL; underrepresented population cohort providing genetic variant data with implications for variant interpretation in MENA populations. Flag: ⬜ NONE — Standard addition

💡 Unsolicited Finds

42552318 · [7/10] Multi-omics integration unravels four molecular subgroups of corticotroph pituitary neuroendocrine tumours with distinct clinicopathological features. → Multi-omics integration of corticotroph pituitary NETs reveals four distinct molecular subgroups with unique clinicopathological profiles; subgroup stratification may inform personalized treatment selection for Cushing's disease and Nelson's syndrome. Flag: ⬜ NONE — Standard addition

📊 Today's Breakdown

By Evidence Maturity

• Exploratory: 17
• Validated: 8

By Watchlist Topic

By Source Type

• peer_reviewed: 25

Topics with Zero 8+ Articles This Run

• CBC / ML Hematology

🔧 Run Notes

• Run: Attempt 2 of 3; repaired from salvage bundle of attempt 1.
• search_logs: Restructured to v1.3 keyed-object format; all 7 PMID coverage fields populated.
• Enum fixes: species_model human_and_mouse→mixed, mouse→animal; evidence_maturity Preliminary→Exploratory; access_level "Full text"→"Publisher full text"; invalid priority_flag_code values corrected to v1.3 enum.
• 42552318 demotion: pipeline_priority HIGH→STANDARD (score 7, no EARLY_CANCER_DETECTION/NOVEL_TREATMENT flag). per_topic_stats updated for precision_oncology_genomics, rare_diseases, sentinel.
• Sentinel: 1,104 raw results; 5 reviewed (cap 10 not fully reached); coverage_complete=false. One article retained (PMID 42552318, STANDARD).
• CBC/ML hematology: 0 results this window.
• Author data incomplete: PMIDs 42552314, 42551830, 42551701, 42551920, 42551126 have truncated esummary author data; classification_confidence=low applied.
• run_status=PARTIAL_SUCCESS due to sentinel coverage_complete=false and some truncated esummary responses.

Generated by Friday (OpenClaw) — attempt 2/3 — 2026-08-05T09:24:20Z